AI medical technology company Laon Medi is expanding its global business by entering the Japanese orthodontic market, following its U.S. market entry after obtaining FDA clearance. Laon Medi announced on the 12th that it has signed a distribution agreement with Corefront, a Japanese medical device distribution company. Through this partnership, Laon Medi is accelerating procedures including registration as a foreign medical device manufacturer, regulatory approvals, and registration with Japan’s Ministry of Health, Labour and Welfare (MHLW). Starting this year, the company will begin full-scale distribution and sales of its AI-based orthodontic setup software, Laon Ortho, in Japan. AI-integrated medical technologies—particularly AI-based dental software—are gaining strong traction in the global market. Following its entry into the U.S., which holds significant influence and market share in the global orthodontics sector, Laon Medi’s expansion into Japan is enabling rapid growth of its international sales network. A Laon Medi representative stated, “Participation in domestic and international dental exhibitions and the establishment of country-specific distribution channels have played a positive role in promoting our AI dental software and increasing awareness of products such as Laon Ortho. Through continued technological advancement and localization, we aim to increase market share in both the U.S. and Japan, while preparing to expand into Southeast Asia and China, where orthodontic markets are rapidly growing, supported by global regulatory approvals.” A representative from Corefront commented, “Even in Japan, which is known for its conservative approach to medical technology adoption, K-medi products have been highly evaluated for their technical excellence and clinical effectiveness. Laon Medi’s fast AI analysis, one-click diagnosis, and digital orthodontic solutions—already clinically validated—align well with the core strengths of K-medi, leading us to see strong potential in the Japanese orthodontic market.” Meanwhile, Laon Medi—selected as a promising SME by Gyeonggi Province—has obtained U.S. FDA clearance for its medical device and entered the U.S. market through a partnership with dental materials company Uclear. The company has also received recognition from orthodontists for its technology and clinical usability at major dental exhibitions and academic conferences, further strengthening its prospects for success in global markets, including Japan.

Laon Medi has entered a strategic partnership with Uclear, a U.S.-based dental distribution company, to begin the official distribution of Laon Ortho across the United States and Latin America. The partnership was formalized at the Greater New York Dental Meeting (GNYDM 2025), one of the world’s largest dental conferences. Bringing FDA-Cleared Orthodontic Technology to the Americas Through this agreement, Laon Medi will supply Laon Ortho, an orthodontic treatment-planning software cleared by FDA 510(k), to the broader Americas market. Uclear, headquartered in Florida, maintains a strong distribution network across the U.S., Mexico, Brazil, and major Latin American regions, enabling rapid expansion and localized support. Uclear will fully transition its existing clear aligner design software lineup to Laon Ortho, establishing a new digital orthodontic ecosystem for clinics, labs, and manufacturers in the region. Integrated Digital Workflow for the Next-Generation Clear Aligners Together, the two companies will introduce a complete digital workflow—from diagnosis and treatment planning to appliance fabrication—powered by Laon Ortho. This includes a joint rollout of direct-print clear aligner systems, designed to reduce production time and modernize in-office and lab workflows. To further enhance product capabilities, Laon Medi plans to initiate collaborative research projects with U.S. orthodontists, incorporating clinical insights into future software advancements. Accelerating Global Expansion Following the U.S. partnership, Laon Medi is receiving increasing interest from multiple international markets, including Japan, and is actively progressing with regulatory approvals and new partnerships worldwide. Message from Laon Medi “This partnership marks our first contract leveraging FDA 510(k) clearance and represents a major milestone as we enter the largest orthodontic market in the world. It is an important step in establishing Laon Ortho as a global standard in digital orthodontics.” Laon Medi continues to draw strong industry attention with its advanced digital orthodontic technologies, including the recently introduced One-Click automated diagnostic workflow. The company was also recognized as a Gyeonggi Province Promising SME and a Family-Friendly Certified Company, reflecting both technological excellence and organizational reliability.

Laon Medi Inc., an AI-powered digital orthodontic solutions company, will participate in the Greater New York Dental Meeting (GNYDM) 2025, held in New York this December. The company will exhibit at Korean Pavilion booth #3721. GNYDM is the largest dental exhibition in North America, attracting more than 30,000 dentists, technicians, and industry professionals. Known for advanced technology demonstrations and clinically focused educational programs, the event serves as a global stage for major companies to introduce new products and innovations. At this year’s meeting, Laon Medi will unveil its “Complete Digital Workflow for Clear Aligners”—a fully integrated pipeline connecting treatment planning, clinical review, and appliance design and manufacturing. The company stated, “Our mission is to transform advanced technology into intuitive systems that any clinician can use. We have consistently incorporated real-world market needs into our product development—and we will apply the same approach as we enter the U.S. market.” Accelerating U.S. Market Entry After FDA Clearance Laon Medi is using GNYDM as the launch point for its U.S. expansion strategy. The company has completed FDA clearance and is preparing to supply its products to clinics, labs, and partners across the United States. In parallel, Laon Medi is expanding discussions with distributors, regional agents, and strategic investors in the U.S., Europe, and the Middle East. Market fit validation and early partnerships will focus on analyzing U.S. orthodontic workflows, insurance and regulatory requirements, and decision-making structures within DSOs. Laon Medi commented, “With FDA clearance secured, we are fully prepared to enter the market immediately. GNYDM marks the beginning of that journey.” Strategic Meetings with Major Global Players During the exhibition, Laon Medi will hold multiple strategic meetings with leading groups, including: DSOs (Dental Service Organizations): Standardized clear aligner workflows for chain practices Aligner Labs / Manufacturers: Unified pipelines connecting planning, review, and production Distributors / Agents: Early-stage partnerships to build U.S. sales and support infrastructure Key Products and Live Demonstrations 1. Laon Ortho – Automated & Manual Treatment Planning Integrated CBCT & IOS–based setup Collaboration features for DSOs, university hospitals, and labs 2. Laon Viewer – Clinical Review & Approval Platform Clinician-centric UX for verifying and approving tooth movement Optimized for shared review and team workflows 3. Appliance Creator – Appliance Design & Manufacturing Module Block-out, trim line, and shell design tools Automatic generation of 3D models for aligner production Laon Medi noted, “At GNYDM, we will demonstrate real clinical cases showing how planning, review, and production are seamlessly connected within a single platform. Customized demos will be available for clinicians, labs, and partners visiting our booth.” For demo scheduling, partnership inquiries, or collaboration discussions during the exhibition, contact: sales@laonmedi.io